HighMark Wealth Management LLC Purchases 60,000 Shares of NeuroPace, Inc. $NPCE

Key Points

• HighMark Wealth Management LLC significantly increased its stake in NeuroPace, Inc. by purchasing an additional 60,000 shares, lifting its total ownership to 63,000 shares and representing a 2,000% increase in the second quarter.
• NeuroPace reported earnings of ($0.26) per share, missing analysts' expectations, despite generating revenue of $23.52 million for the quarter, exceeding estimates.
• Analysts have mixed sentiments on NeuroPace, with Wells Fargo lowering its price target to $15.00 while maintaining an "overweight" rating, and the stock currently holds a consensus rating of "Moderate Buy" with an average target price of $16.60.

HighMark Wealth Management LLC lifted its position in shares of NeuroPace, Inc. (NASDAQ:NPCE - Free Report) by 2,000.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 63,000 shares of the company's stock after purchasing an additional 60,000 shares during the period. HighMark Wealth Management LLC owned 0.19% of NeuroPace worth $702,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the company. Rhumbline Advisers grew its holdings in NeuroPace by 15.2% during the first quarter. Rhumbline Advisers now owns 17,227 shares of the company's stock worth $212,000 after purchasing an additional 2,267 shares during the period. BNP Paribas Financial Markets acquired a new stake in shares of NeuroPace in the fourth quarter valued at approximately $29,000. Charles Schwab Investment Management Inc. boosted its stake in shares of NeuroPace by 7.4% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 39,237 shares of the company's stock worth $482,000 after acquiring an additional 2,700 shares during the period. GAMMA Investing LLC acquired a new position in shares of NeuroPace during the 1st quarter worth approximately $53,000. Finally, Birchview Capital LP raised its stake in NeuroPace by 64.4% in the 1st quarter. Birchview Capital LP now owns 16,442 shares of the company's stock valued at $202,000 after acquiring an additional 6,442 shares during the period. 78.83% of the stock is currently owned by institutional investors and hedge funds.

NeuroPace Stock Performance

Shares of NASDAQ NPCE opened at $10.43 on Friday. The company has a debt-to-equity ratio of 3.02, a current ratio of 5.47 and a quick ratio of 4.51. The firm has a market cap of $345.02 million, a price-to-earnings ratio of -12.42 and a beta of 1.91. The stock's fifty day moving average price is $9.36 and its two-hundred day moving average price is $11.04. NeuroPace, Inc. has a one year low of $5.45 and a one year high of $18.98.

NeuroPace (NASDAQ:NPCE - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.02). NeuroPace had a negative return on equity of 168.61% and a negative net margin of 29.29%.The firm had revenue of $23.52 million for the quarter, compared to analyst estimates of $23.08 million. NeuroPace has set its FY 2025 guidance at EPS. On average, equities analysts forecast that NeuroPace, Inc. will post -1 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. Wells Fargo & Company cut their price target on NeuroPace from $17.00 to $15.00 and set an "overweight" rating for the company in a report on Wednesday, August 13th. Zacks Research cut shares of NeuroPace from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 13th. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $16.60.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.